Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study

Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diag...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jarosław B. Ćwikła, Marek Roslan, Iwona Skoneczna, Monika Kempińska-Wróbel, Michał Maurin, Wojciech Rogowski, Barbara Janota, Anna Szarowicz, Piotr Garnuszek
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	prostate cancer molecular imaging prostate specific membrane antigen (PSMA) [<sup>99m</sup>Tc]Tc-PSMA-T4 Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/a0e5ca092f78461a9d09f2c9eaa41c14
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0e5ca092f78461a9d09f2c9eaa41c14
record_format	dspace
spelling	oai:doaj.org-article:a0e5ca092f78461a9d09f2c9eaa41c142021-11-25T18:39:24ZInitial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study10.3390/ph141111071424-8247https://doaj.org/article/a0e5ca092f78461a9d09f2c9eaa41c142021-10-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1107https://doaj.org/toc/1424-8247Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diagnosis of patients with PCa. We conducted a single site, prospective, preliminary case series study that included 31 patients with PCa; all had undergone clinical, biochemical or imaging examination and exhibited clear or suspicious active disease or clinical/biochemical recurrence of PCa. Whole-body (WB) SPECT/CT after i.v. administration of [<sup>99m</sup>Tc]Tc-PSMA-T4 was utilized; acquisition images were obtained at three time points. The clinical value of the images was assessed in regard to the evaluation of tumor extent in patients with confirmed PC that qualified for initial therapy and the evaluation of tumor recurrence; both provided encouraging results. The late acquisition of WB-SPECT resulted in better lesions delineation. The results of the analysis of the sensitivity/specificity were: 92%/100% in cases of primary cancer, 83%/100% in terms of pelvic lymph nodes disease, 100%/95% in other lymph nodes and soft tissue involvement, respectively, and bone mets were both 100%. An oncotropic SPECT [<sup>99m</sup>Tc]Tc-PSMA-T4 can help in selecting a rational therapeutic strategy for a patient with an initial diagnosis of PCa by assessing the extent of cancer and also after complex radical or palliative therapy in case of biochemical recurrence for re-staging.Jarosław B. ĆwikłaMarek RoslanIwona SkonecznaMonika Kempińska-WróbelMichał MaurinWojciech RogowskiBarbara JanotaAnna SzarowiczPiotr GarnuszekMDPI AGarticleprostate cancermolecular imagingprostate specific membrane antigen (PSMA)[<sup>99m</sup>Tc]Tc-PSMA-T4MedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1107, p 1107 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer molecular imaging prostate specific membrane antigen (PSMA) [<sup>99m</sup>Tc]Tc-PSMA-T4 Medicine R Pharmacy and materia medica RS1-441
spellingShingle	prostate cancer molecular imaging prostate specific membrane antigen (PSMA) [<sup>99m</sup>Tc]Tc-PSMA-T4 Medicine R Pharmacy and materia medica RS1-441 Jarosław B. Ćwikła Marek Roslan Iwona Skoneczna Monika Kempińska-Wróbel Michał Maurin Wojciech Rogowski Barbara Janota Anna Szarowicz Piotr Garnuszek Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
description	Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diagnosis of patients with PCa. We conducted a single site, prospective, preliminary case series study that included 31 patients with PCa; all had undergone clinical, biochemical or imaging examination and exhibited clear or suspicious active disease or clinical/biochemical recurrence of PCa. Whole-body (WB) SPECT/CT after i.v. administration of [<sup>99m</sup>Tc]Tc-PSMA-T4 was utilized; acquisition images were obtained at three time points. The clinical value of the images was assessed in regard to the evaluation of tumor extent in patients with confirmed PC that qualified for initial therapy and the evaluation of tumor recurrence; both provided encouraging results. The late acquisition of WB-SPECT resulted in better lesions delineation. The results of the analysis of the sensitivity/specificity were: 92%/100% in cases of primary cancer, 83%/100% in terms of pelvic lymph nodes disease, 100%/95% in other lymph nodes and soft tissue involvement, respectively, and bone mets were both 100%. An oncotropic SPECT [<sup>99m</sup>Tc]Tc-PSMA-T4 can help in selecting a rational therapeutic strategy for a patient with an initial diagnosis of PCa by assessing the extent of cancer and also after complex radical or palliative therapy in case of biochemical recurrence for re-staging.
format	article
author	Jarosław B. Ćwikła Marek Roslan Iwona Skoneczna Monika Kempińska-Wróbel Michał Maurin Wojciech Rogowski Barbara Janota Anna Szarowicz Piotr Garnuszek
author_facet	Jarosław B. Ćwikła Marek Roslan Iwona Skoneczna Monika Kempińska-Wróbel Michał Maurin Wojciech Rogowski Barbara Janota Anna Szarowicz Piotr Garnuszek
author_sort	Jarosław B. Ćwikła
title	Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
title_short	Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
title_full	Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
title_fullStr	Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
title_full_unstemmed	Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
title_sort	initial experience of clinical use of [<sup>99m</sup>tc]tc-psma-t4 in patients with prostate cancer. a pilot study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a0e5ca092f78461a9d09f2c9eaa41c14
work_keys_str_mv	AT jarosławbcwikła initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT marekroslan initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT iwonaskoneczna initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT monikakempinskawrobel initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT michałmaurin initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT wojciechrogowski initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT barbarajanota initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT annaszarowicz initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy AT piotrgarnuszek initialexperienceofclinicaluseofsup99msuptctcpsmat4inpatientswithprostatecancerapilotstudy
_version_	1718410852949819392

Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study

Ejemplares similares